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Background: Hormone Therapy (HT) reduces the risk of breast cancer recurrence and mortality in
women with breast cancer. Despite these clinical benefits, rates of HT non-adherence and non-
persistence are high. Research suggests this may be due to the impact of HT side effects. However, lit-
tle research has explored the individual contribution of side effects to non-adherence and non-
persistence behaviours, thereby hindering the implementation of targeted intervention strategies. Our
aim is to review the published literature on breast cancer survivors’ lived experiences of HT side effects
and explore how these may be related to non-adherence and non-persistence behaviour.
Methods: Electronic searches were conducted from inception to May 2020, utilising Cochrane CENTRAL,
Medline, Embase, Web of Science and PsycINFO databases. Searches included a combination of terms
related to breast cancer, adherence, hormone therapy and side effects.
Results: Sixteen eligible papers were identified, and study quality was high. Data were thematically
synthesised into four analytical themes, which encompassed 13 descriptive sub-themes: ‘Daily impact of
side-effects’, ‘Role of Health Care Professionals’, ‘Managing HT side-effects’, and ‘Weighing up the pros
and cons’.
Conclusions: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support
from healthcare providers leads to self-management strategies, which negatively affects adherence and
persistence behaviour.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Breast cancer is the most common cancer in the UK, accounting
for 15% of all new cases and is the third most common cause of
cancer-related deaths [1]. Hormone Therapy (HT), is a treatment
that suppresses hormone production or that interferes with hor-
mone receptor signalling in order to prevent tumour growth, is
prescribed to breast cancer survivors for up to ten years following
diagnosis. Around three quarters of breast cancers are hormone-
receptor-positive and are treatable with HT. The most commonly
prescribed HTs are Selective Estrogen Receptor Modulators
(SERMS) (e.g. Tamoxifen) and Aromatase Inhibitors (AI) (e.g.
Letrozole, Anastrozole and Exemestane) [2]. When taken as pre-
scribed, HT reduces the risk of breast cancer recurrence by 40% and
mortality by a third [3]. However, despite its clinical efficacy for
recurrence prevention, many cancer survivors do not take their HT
as prescribed. Approximately 50% of women take less than 80% of
the prescribed dosage [4] and up to 50% discontinue their treat-
ment by the fifth year of prescription [5]. This pattern of poor
persistence and non-adherence is associated with increased odds
of breast cancer recurrence and mortality [6]. Adherence to and
persistence with hormone therapy is therefore considered a key
determinant of disease-free survival.
Adherence is defined as the degree to which an individual's
behaviour corresponds with agreed treatment recommendations in
terms of dose, timing and frequency, whereas persistence refers to
the duration of treatment from initiation to discontinuation [7].
Recent research has begun to explore the mechanisms that impact
upon adherence and persistence behaviour and has identified
sociodemographic, clinical and psychosocial characteristics as po-
tential risk factors [8,9]. Sociodemographic variables such as age,
socioeconomic status, ethnicity, education and out of pocket costs
of medications have been shown to negatively impact HT adher-
ence and persistence [10e12]. Similarly, clinical characteristics such148as switching between treatments (e.g. from Tamoxifen to Letrozole)
is also negatively associated with adherence and persistence [12].
Whilst the identification of sociodemographic and clinical risk
factors facilitate our understanding of those individuals most likely
to be non-adherent and non-persistent, they have limited value
when considering strategies to promote positive behaviour change.
However, identifying psychosocial characteristics that increase the
risk of non-adherence and non-persistence to HT does provide a
potential pathway to behaviour change interventions to promote
adherence and persistence.
In a recent review of barriers and facilitators of HT adherence
and persistence [9], several factors were identified as possible
intervention targets due to their impact on adherence and persis-
tence behaviour. One of these factors was categorised as ‘side ef-
fects from HT’ and included cognitive, gynaecological,
musculoskeletal and sleep/fatigue-related symptoms. Similarly,
numerous studies have found that patients' experience of HT side
effects (joint pain, hot flushes, night sweats, fatigue), affect adher-
ence and rates of treatment discontinuation [8,13,14], potentially
because the adverse effects of treatment outweigh the perceived
benefits [15]. Therefore, unlike sociodemographic and clinical fac-
tors that are not amenable to change, side effects are suggested
intervention targets because their effective management has the
potential to increase long-term HT adherence and reduce rates of
treatment discontinuation. However, the contribution of specific
side effects to HT non-adherence and non-persistence is poorly
understood, making the development and prioritisation of targeted
intervention strategies difficult. Many studies prefer instead to
utilise quantitative questionnaire-based methodologies to report
an overall side effect profile where presence/absence of side effects
are reported as a single yes/no variable [16e18]. In addition, a lack
of consistency in published terminology (e.g. adherence, compli-
ance, persistence, continuance), definitions (e.g. medication
possession ratio (MPR) of 80% or discontinuation before 5 years),
data measurements and sources (e.g. medical records, clinician
checklists, self-report questionnaires) make cross-study compari-
son challenging [19]. Therefore, greater consistency and qualitative
understanding of the impact of individual side effects would help to
identify and quantify the specific psychosocial determinants of
non-adherence and non-persistence that are modifiable through
intervention.
Two recent reviews of qualitative research in this area [19,20]
have identified that adherence to HT is negatively impacted by the
presence and severity of side effects. However, these reviews were
broad in scope, considering multiple patient-related factors (e.g.
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enced adherence and persistence. Therefore, whilst these studies
provide valuable insight into the lived experience of taking HT,
further qualitative work must explore the primary motivations for
non-adherence and non-persistence if tailored approaches for
managing side effects are to improve adherence and persistence
behaviour in breast cancer survivors. Therefore, the aims of this
review are to (i) synthesise breast cancer survivors’ lived experi-
ences of HT side effects and (ii) conduct an in-depth exploration of
how these experiences may influence adherence and persistence
behaviour. By synthesising experiences of side effects and how they
are perceived to influence adherence and persistence behaviour,
potential facilitators and barriers to adherence and persistence will
be identified. This will inform the implementation of targeted
evidence-based interventions to improve adherence to HT and
reduce rates of recurrence and mortality.
2. Method
This review has followed the ENTREQ statement [21] and has
adopted Thomas and Harden's (2008) [22] approach to thematic
synthesis.
2.1. Search strategy
A comprehensive search strategy was developed and adapted
from Moon et al. (2017) [9]. A combination of search terms related
to 1) breast cancer, 2) adherence and persistence 3) hormone
therapy and 4) side effects were included. A full copy of the search
strategy is included as a supplementary file. Electronic searches
were performed from inception to May 2020 using the following
databases: Cochrane CENTRAL, Medline, Embase, Web of Science,
and PsycINFO. The review protocol was registered on the PROS-
PERO database on August 13, 2020 (CRD42020192481). As outlined
in the protocol, we originally planned to conduct a mixed-methods
review of the literature on the impact of HT side effects on adher-
ence and persistence. However, the initial search generated such a
significant volume of quantitative and qualitative studies that it
was decided to be more valuable to publish two separate reviews.
2.2. Inclusion criteria
Studies were included if they utilised a qualitative methodology
to investigate the impact of HT side effects on adherence and/or
persistence in adult, female breast cancer survivors. No exclusion
criteria were applied to year of publication. Papers were excluded if
they were not available in English. Full details of the inclusion/
exclusion criteria are presented in Table 1.
2.3. Study selection
Search results were uploaded to ‘Covidence’ (Melbourne,
Australia), an online tool used to manage systematic reviewTable 1
Inclusion and exclusion criteria.
Inclusion Criteria
1) Female participants
2) Aged 18 years or older
3) Prescribed adjuvant hormone therapy for primary breast cancer
4) Study conducted in either clinical practice or trials
5) Studies present qualitative data on side effects of adjuvant
hormone therapy
149screening and data extraction. After the removal of duplicates, titles
and abstracts were independently screened by two authors (NP &
SA) using a pre-defined screening tool based on the inclusion/
exclusion criteria. If an abstract did not provide sufficient exclusion
information, then the article was obtained for full text screening.
Full text screening was conducted independently by the same two
authors. Screening conflicts were resolved through discussion with
a third reviewer (LF). Efforts were made to contact authors of pa-
pers where the full text was unavailable and to obtain full reports
from conference abstracts.
2.4. Data extraction
Data were extracted from the method sections of included pa-
pers to obtain details of the study purpose, sample size, participant
characteristics, study design and method of analysis. Data extrac-
tion was conducted by two authors (NP & SA) and all text labelled
as ‘results’ or ‘findings’ were extracted to permit synthesis of all
relevant data [22].
2.5. Quality appraisal
Selected studies were assessed for quality using the Joanna
Briggs Institute Critical Appraisal Checklist for Qualitative Research
[23]. Two authors (NP & SA) independently assessed the quality of
the included studies by scoring each article against the checklist
criteria of “met”, “not met”, “unclear” and “not applicable”. The
quality criteria included domains related to method and method-
ology, data analysis, interpretation of results and reflexivity. An
additional item was added to the quality assessment tool to assess
whether the included studies had provided a clear description of
adherence and persistence. This additional item was scored using
the same checklist criteria. Any disagreements were resolved by
consulting a third author (LF). In this review no study was elimi-
nated based on quality assessment.
2.6. Data analysis
Data were analysed according to the thematic synthesis
approach developed by Thomas & Harden [22]. This approach is
influenced by both meta-ethnography and grounded theory [24].
The first stage of this approach is inductive, coding results line-by-
line, then re-examining codes across studies to identify similarities.
Following Thomas and Harden's [22] use of axial coding, codes
were then re-assessed to ensure they accurately captured the data
and additional levels of code were assigned when the text could be
more appropriately represented. Descriptive themes were then
developed by organising codes together into logical groups. The
initial coding was conducted by SA, with NP contributing to the
final interpretative stage. Analytical themes were developed from
the data to explore women's lived experience of taking HT and the
influence of HT side effects on adherence and persistence
behaviour.Exclusion Criteria
1) Articles that are not published in English or full text is not available
2) Studies including only DCIS or Stage IV patients
3) Studies which do not include primary data such as systematic reviews
and protocols
4) Studies investigating initiation to HT
5) Studies relating to screening or diagnosis
6) Studies not using human subjects
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3.1. Study characteristics
A total of 5107 articles were identified. After removing quanti-
tative studies, duplicates and screening titles and abstracts, 456
full-text articles were screened. Sixteen articles were included in
the review. Full details of the search results and reasons for
exclusion are shown in the PRISMA diagram (Fig. 1). The included
studies were published between 2013 and 2019. Studies were
published in 7 countries, with almost half (n ¼ 7) originating from
the USA. Sample sizes ranged from 12 to 54 participants: the total
number of participants interviewed was 445 (excluding Mao et al.
(2013) as this study included messages posted on a website) [25].
For full study characteristics information, see Table 2.
Side effects were self-reported by participants and both physical
and psychological side effects from HT were reported in the
included studies. Themost commonly reported physical side effects
were fatigue [26e33], hot flashes [26,27,29e31,33e37], nightFig. 1. Prisma flow diagra
150sweats [29,31,33,34,37], musculoskeletal pain [25e27,29,31e38],
weight gain [26e29,32,33,37], alopecia [29,32,33,35,37], sexual
dysfunctions including loss of sexual interest [27,29,30,33,36],
vaginal dryness [26,27,29,31,33e37] and pain during sex [26,33].
The most commonly reported psychological side effects included
depression [26,27,30e32,35,36,38], insomnia or sleep disturbance
[32e35,40], suicidal feelings [29], mood swings [27], impaired
memory and concentration [25,30,31,34], anxiety [30e32] and
anger [26,33]. Two studies [39,40] discussed side effects generally,
and did not specify which side effects were experienced by par-
ticipants. Details of specific side effects reported in each study are
included in Table 3.3.2. Quality assessment
Overall, the methodological quality of the included studies was
judged to be high. However, only 50% of studies provided a clear
description of adherence and persistence. Details of the quality
assessment can be seen in Table 4.m of study selection.
Table 2
Characteristics of included studies.
Study
Reference
Country Design/Method Population Sample
Size





Sweden Focus group Women treated with Tamoxifen after breast
cancer surgery
25 Median age: 62 years (range 42e80); 92%
Married/co-habiting, 8% Single; 40% Retired;
60% Employed full or part time
Content
analysis
To explore women's experiences with HT
Bedi (2018)
[26]
USA Focus group Hormone receptor-positive breast cancer
survivors under age 64 who had been
prescribed ET since 2000; 50% on Tamoxifen,
41% on Aromatase Inhibitors, and 9% had
switched.
22 Median age: 52 years when first prescribed ET
(Range: 37e63 years); 64% Caucasian, 23%
African American, and 14% Other Race; 18%
High School Diploma, 14% Associate Degree,
41% Bachelors' Degree, 18% Post-Baccalaureate
Degree, And 9% Preferred Not to Answer
Grounded
theory
To understand from the survivor perspective
which modifiable factors could have the





USA Mixed method -
interview
Breast cancer survivors who were prescribed
adjuvant hormone therapy (i.e., Tamoxifen or
AI).
27 Mean Age: 57 Years (Range ¼ 49e86 Years); 27
Non-Hispanic White, 1 Non-Hispanic Black, 2
Hispanic; 22 Married, 8 Other; 4 High School
Diploma, 5 Some College Or Technical School,
15 Bachelor's Degree, 6 Graduate Degree
Grounded
theory
To describe survivors' reported appraisal and
management of medication-related side effects
and deconstruct survivors' decisions to initiate,




USA Interview Early-stage breast cancer, age 65 years and
older taking AI
27 Mean age: 73.3 years (range 66e91); 4
Divorced, 1 Never married, 12 Married or living
as married, 9 Widowed, 1 Separated;
Grounded
theory
To explore how survivors of breast cancer made
decisions about persisting with AIs, including
specific challenges as well as attempts to
manage them.
7 High school diploma, 2 Some College, 9




UK Interview Women who had been prescribed adjuvant
hormone therapy, 19 Tamoxifen, 4 AI and 9




Identify the factors that influence whether
women adhere to or do not adhere to adjuvant
hormone therapy
median age: 59 (Range 37e77)
15 (79%) Married, 1 (5%) Single, 3 (16%)
Separated - Widow;
1 (5%) O0 O” level, GCSE, or equivalent, 16 (84%)
College or university degree, 2 (11%)
Postgraduate qualification;
Non-adherers
median age: 64 (Range 53e76);
10 (77%) Married, 2 (15%) Single, 1 (8%)
Separated;




Ireland Interview Womenwith stage I-III breast cancer prescribed
adjuvant hormonal therapy purposively
sampled by their medication taking behaviour
at two cancer centres.
31 Mean age 51 years (SD ± 10); Thematic
analysis
To investigate influences on adjuvant hormonal
therapy Medication Taking Behaviour in
women with stage IeIII breast cancer.
7 Single, 24 Married/cohabiting;
Employed: 16 Yes, 15 No
Cheng et al.
(2017) [28]
China Interview Breast cancer survivors (<5 years after
diagnosis)
19 Mean age: 54 years (range 41e65 years); 95% of
the participants were unemployed or retired
Content
analysis
Reveal Breast Cancer Survivor's views and




UK Interview Women who had been prescribed tamoxifen or
aromatase inhibitors (anastrozole or letrozole)
and had been taking this medication for 1e5
years
30 Ages: <50 years 2 (7%), 50e64 years 15 (50%),









Women's experiences of taking adjuvant
hormone therapy; their understandings and
reasons for taking or not taking medication and
the factors which influenced adherence or non-
adherence and the information and support
they received or desired.

















Table 2 (continued )
Study
Reference
Country Design/Method Population Sample
Size
Sample Characteristics Analysis Research Question
3 (10%) premenopausal, 7 (23%),





Canada Interviews and focus
groups
Women aged 18 years or older, diagnosed with
hormone receptor-positive breast cancer, had a
first adjuvant hormone therapy prescription for
early breast cancer within the last two years
and sufficient fluency in French. 19 Tamoxifen,
3 Letrozole, and 21 Anastrozole
43 Ages: 49: 6, 50e59: 17, 60e69: 10, 70: 10; Thematic
Analysis
Identify women's attitudinal, normative, and
control beliefs regarding adjuvant hormone
therapy adherence that could be targeted by an
intervention offered in the community
pharmacy setting.




Italy Interview Women aged between 44 and 75 years,
diagnosed with breast cancer, who were being
treated with endocrine therapy mainly
Tamoxifen.




To explore the experiences of adherence to
hormone therapy in women with breast cancer.
5 Single, 15 Married, 5 Divorced, 2 Widowed
Lambert et al.
(2018) [37]
Canada Interview Women diagnosed with HR þ stage I to III
breast cancer, without a prior cancer diagnosis,
recurrence of breast cancer, or secondary cancer
diagnosis (excluding non-melanoma skin
cancer), who had completed primary cancer
treatment, were fluent in English, aged 18e79
years at diagnosis, and prescribed Adjuvant
Hormone Therapy.




To explore breast cancer survivors' experiences
and perspectives of adjuvant hormone therapy
use to describe how personal, social, and




USA Mixed method e online
forum posts
Posts collected from breast cancer message







Data on sample not collected. Content
Analysis
To evaluate the volume and frequency of AI-




UK Interview Breast cancer survivors who had been
prescribed tamoxifen
32 Mean age: 55 years (range: 36 to 77, SD¼ 10.6);
16 Post-Menopausal, 5 Pre-Menopausal, 5
Perimenopausal, 6 Unsure; 24 White, 5 Black
British, 2 Asian/Asian British, 1 Mixed
Thematic
Analysis
To elicit abroad understanding of women's lived
experiences of tamoxifen, their motivation to
adhere to treatment and identify reasons for




USA Interview Women aged at least 65 years old, started an AI
for loco-regional (Stage I, II or III) breast cancer
4e36 months prior to enrolment and were in
charge of taking their own medications.
54 Mean age: 73.3 years (range ¼ 66e91); Thematic
Analysis
To describe and compare how women treated
for primary early-stage breast cancer either
persisting or not persisting with an AI received,
interpreted, and acted upon AI-related
information.
44 White, 3 Latina, 3 Japanese, 2 Chinese, 1
Korean, 1 African American; 24 Married, 2
Never married, 16 Widowed, 10 Divorced, 2
Separated;
9 High School Graduate, 7 Some College, 19
College Graduate, 5 Some Graduate School, 14
Graduated Grad School; Household Income: 14:
$21k-$40,999, 8: $41k-60,999, 13: $61k-80,999,




USA Focus group Breast cancer survivors, aged 50 years or older,
with Adjuvant Hormone Therapy-related
symptoms
14 Mean age: 58.8 years (SD: 6.7); 100% Caucasian;
79% Married; 21% Employed, 79% Not Working
(retired, disabled, not able to find a job)
Thematic
Analysis
To explore survivors' recollection of the
conversation with the medical oncologist about
starting Adjuvant Hormone Therapy,
experiences with Adjuvant Hormone Therapy-
related symptoms, Adjuvant Hormone Therapy-
related symptom management, challenges to
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1533.3. Thematic synthesis
Four analytical themes were derived from the data. The first,
‘Daily impact of HT side effects’, relates to the influence of HT on all
aspects of functioning, including work, relationships, social life and
physical and mental health. The second theme, ‘Role of Health Care
Professionals (HCPs)’, highlights the important role that HCPs play in
a patient's HT adherence behaviour. Third, ‘Managing HT side effects’
summarises the strategies used by patients to reduce HT side ef-
fects. Finally, ‘Weighing up the pros and cons’ highlights the key
aspects involved in HT adherence and persistence decision making.
For each of these analytical themes, several descriptive themes
were identified, which are detailed in Table 5 below.
3.3.1. Daily impact of HT side effects
Many women reported experiencing intense side effects from
HT, describing them as “violent” and “excruciating” [37]. Side ef-
fects were reported to significantly impact on women's quality of
life, which as a result impacted upon their mental wellbeing. This
created a heavy emotional burden which led women to question
their identity and to experience depressive and suicidal states
[30,32,33,36,38]. Physical side effects such as joint pain had a
debilitating effect, leaving one individual reliant on a cane for
walking [32]. Several participants experienced pain throughout the
whole body, severely restricting their movement. This limited their
ability to perform household chores, personal care and even simple
tasks like getting out of bed in the morning [30,32]. Ability to
perform physical tasks at work was also affected [31]. As well as
restricting physical capability at work, cognitive side effects of
hormone therapy (including difficulty concentrating and memory
loss) made it difficult for women to focus on tasks [41]. Women also
described themselves as more forgetful, which was exacerbated by
the interruption of sleep due to hot flushes, night sweats and joint
pain [31,34,35,37]. This loss of sleepwas related to lack of energy for
social activities and professional responsibilities [31]. Professional
confidencewas also affected by body image concerns due toweight
gain [38]. In addition to debilitating physical side effects, the
“disabling” effect [36] of adjuvant HT treatment had severe
emotional implications. Women became socially withdrawn and
avoided typical daily activities due to fear of embarrassment from
unpredictable side effects and losing trust in their own bodies [37].
A loss of sexual desire and menopausal symptoms such as hot
flashes and vaginal dryness put strain on romantic relationships
[33,38], which was distressing for several participants [36,38].
Women also reported that side effects impacted on other inter-
personal relationships, such as relationships with family members
and friends, as they felt that they were unable to interact with them
as they had done previously [38], or that they could not talk to them
about the side effects they were experiencing [31]. Menopausal
symptoms also impacted women's sense of identity, as symptoms
such as musculoskeletal pain, loose teeth, vaginal dryness and al-
opecia created a sense of premature ageing, leading one individual
to describe feeling “like a 90-year-old woman” [34].
3.3.2. Role of Health Care Professionals (HCPs)
A lack of pre-emptive information about the nature and severity
of HT side effects was highlighted consistently in the literature,
with women reporting feeling unprepared for what they experi-
enced. Participants explained that they had been informed of the
side effects of primary treatment such as chemotherapy [27], but
expressed the desire to be forewarned about the potential side
effects of hormone treatment [26]. Some had been prepared for
side effects but were surprised by the range and intensity of the
menopausal symptoms [34]. Women stated that this lack of infor-
mation was a significant issue, as informed expectations would
Table 3
Reported side effects.
Side Effect N Study Side Effect Reported in
Alopecia 5 Ahlstedt Karlsson et al. (2017), Harrow et al. (2014), Lambert et al. (2018), Wells et al. (2016), Humphries et al. (2018)
Anxiety 3 Moon et al. (2017), Van Londen et al. (2014), Wells et al. (2016)
Brittle Fingernails 1 Bleuthmann et al. (2017)
Cognitive dysfunction (memory problems,
issues with concentration)
4 Bleuthmann et al. (2017), Mao et al. (2013), Van Londen et al. (2014), Moon et al. (2017)
Constipation 1 Wells et al. (2016)
Diarrhoea 1 Lambert et al. (2018)
Depression/low mood/mood swings 11 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019), Braeur et al. (2016), Brett et al., 2018), Humphries et al. (2018),
Iacorossi et al. (2018), Moon et al. (2017), Wells et al. (2016), Brett et al. (2018), Van Londen et al. (2014), Wells et al.
(2016)
Fatigue 8 Ahlstedt Karlsson et al. (2017), Cheng et al. (2017), Harrow et al. (2014), Moon et al. (2017), Van Londen et al. (2014),
Wells et al. (2016), Brett et al., 2018), Bedi et al. (2019),
Facial Flushing 1 Bleuthmann et al. (2017)
Hot Flashes 12 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019), Bleuthmann et al. (2017), Humphries et al. (2018), Iacorossi et al.
(2018), Lambert et al. (2018), Van Londen et al. (2014), Van Londen et al. (2014), Wells et al. (2016), Brett et al.
(2018), Harrow et al. (2014), Moon et al. (2017),
Insomnia/sleep disturbances 5 Harrow et al. (2014), Moon et al. (2017), Van Londen et al. (2014), Wells et al. (2016)
Lambert et al. (2018)
Loss of Sexual interest 5 Ahlstedt Karlsson et al. (2017), Brett et al. (2018), Iacorossi et al. (2018), Harrow et al. (2014), Moon et al. (2017),
Liver Problems 1 Iacorossi et al. (2018)
Musculoskeletal pain 12 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019), Bleuthmann et al. (2017), Braeur et al. (2016), Harrow et al. (2014),
Humphries et al. (2018), Iacorossi et al. (2018), Lambert et al. (2018), Mao et al. (2013), Van Londen et al. (2014),
Wells et al. (2016), Brett et al., 2018)
Nausea 2 Harrow et al. (2014), Wells et al. (2016),
Osteoporosis 1 Cheng et al. (2017)
Pain during sex 2 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019),
Side effects not specified 2 Pieters et al. (2019), Cahir et al. (2015)
Suicidal feelings 1 Harrow et al. (2014)
Sexual Dysfunction 1 Van Londen et al. (2014)
Sweating/night sweats 5 Ahlstedt Karlsson et al. (2017), Bleuthmann et al. (2017), Harrow et al. (2014), Lambert et al. (2018), Van Londen et al.
(2014),
Vaginal dryness 9 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019), Bleuthmann et al. (2017), Brett et al. (2018), Harrow et al. (2014),
Humphries et al. (2018), Iacorossi et al. (2018), Lambert et al. (2018), Van Londen et al. (2014)
Weight gain 7 Ahlstedt Karlsson et al. (2017), Bedi et al. (2019), Brett et al., 2018), Cheng et al. (2017), Harrow et al. (2014), Lambert
et al. (2018), Wells et al. (2016)
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closely to their prescription [27,30]. Many struggled to identify
whether menopausal symptoms were due to HT, normal ageing or
pre-existing conditions [38] and this confusion was linked to
delaying seeking help, which led to worsening of side effects and in
some cases, discontinuation of treatment [40]. Although some
women recalled having initial conversations about the purpose of
adjuvant treatment, they struggled to describe these conversations,
and many were sure they had received little warning about po-
tential side effects [31]. Many were informed of adjuvant treatment
during their first cancer treatment consultation and had been too
“bombarded” [27] with information to fully comprehend orTable 4
Results of the quality assessment of included studies.
Study Reference Q1 Q2 Q3 Q4
Ahlstedt Karlsson et al. (2019) Y Y Y Y
Bedi (2019) Y Y Y Y
Bluethmann et al. (2017) Y Y Y Y
Brauer et al. (2016) Y Y Y Y
Brett et al. (2018) Y Y Y Y
Cahir et al. (2015) Y Y Y Y
Cheng et al. (2017) Y Y Y Y
Harrow et al. (2014) Y Y Y Y
Humphries et al. (2018) Y Y Y Y
Iacorossi et al. (2018) Y Y Y Y
Lambert et al. (2018) Y Y Y Y
Mao et al. (2013) Y Y Y Y
Moon et al. (2017) Y Y Y Y
Pieters et al. (2019) Y Y Y Y
Van Londen et al. (2014) Y Y Y Y
Wells et al. (2016) Y Y Y Y
154remember what information they had been given.
The transition from “receiving” primary treatment (chemo-
therapy, surgery and radiotherapy) [38] to being largely responsible
for their own medication use, marked a significant change for
breast cancer survivors. Participants described “falling through the
gaps” [27] of the healthcare system after finishing primary treat-
ment, with some feeling that their primary care practitioner did not
possess sufficient specialist knowledge to support them with
adjuvant HT [26,33] and that other Health Care Professionals
(HCPs) (such as breast cancer nurses and oncologists) [29,31] were
too busy supporting patients in primary therapy to answer their
questions. This resulted in women feeling unsupported and left toQ5 Q6 Q7 Q8 Q9 Q10 Q11a
Y N N Y Y Y N
Y N N Y Y Y N
Y N N Y Y Y N
Y Y N Y Y Y N
Y N N Y Y Y Y
Y N N Y Y Y Y
Y Y N Y Y Y N
Y Y N Y N Y Y
Y N N Y Y Y Y
Y N N Y Y Y Y
Y N N Y Y Y Y
Y N N N Y Y N
Y N N Y Y Y Y
Y Y Y Y Y Y Y
Y N N Y Y Y N
Y Y N Y Y Y N
Table 5
Analytical themes, descriptive themes and illustrative extracts.
Analytical theme Descriptive themes Illustrative extracts
Daily impact of HT
side effects
Social functioning “I started towithdraw from social situations. I didn't trust my body to co-operate. I missed out on quite a few things,
because I was too afraid that [due to the diarrhoea] I would have to run or, changemy clothes or have a shower. And
make amess in public. Emotionally, it was devastating” (Lambert et al., 2018; p.5) “It just stops you getting onwith
your life. You have been through surgery, then chemotherapy, then you take the hormone drugs. You get to the
stage when you want to get back to normal, but these drugs stop you doing that” (Brett et al., 2018; p.296)
Inter-personal relationships “One of the things that upset me most at the time [was that] I lost all interest in sex overnight e it didn't help my
husband as you can imagine.” (Brett et al., 2018; p.294) “And I have two, three grandchildren. I love children…. So,
when I see them, I want to playwith them… but physically I can't do it. So, thatmakesmedreally upsets me. I think
that's the thing.” (Brauer et al., 2016; p.995)“Well your friends and relatives don't want to hear about it
[symptoms].” (Van Londen et al., 2014; p.5)
Ability to work “I am more forgetful. I work harder at work to do the same job that I used to just do. It's harder for me to stay
focused, to concentrate, to think clearly, to remember everything.” (van Londen et al., 2014; p.5) “I am unable to
undertake too heavy/many physical tasks. I should perform light work only. For example, I easily feel tired when
cooking. I have to take a break and lie down on the bed for 15 min. After boosting my energy, I get up and continue
to cook.” (Cheng et al., 2017; p.1043)
Physical health “There are days that all of you is in pain, all the body …. A pain that you don't know what is hurting …. and it is so
horrible … you try to be still so it doesn't hurt. You can't cook, you can't clean, you can't even bathe because … the
pain is in all your body.” (Wells et al., 2016; p.7) “I felt like a 90-year-old woman.” (Bluethmann et al., 2017; p.6)
Mental Wellbeing “I just don't feel exactly like myself [on Arimidex®]. I don't feel real clear-headed, and I feel groggy a lot of the time.
If you're not sleeping well, you don't know if one thing causes the other.” (Bluethmann et al., 2017; p.6) “I felt so
low, was having suicidal thoughts, really didn't feel like myself at all, I was in so much pain and that I'd made the
decision that I was going to come off tamoxifen.” (Moon et al., 2017; p.18)
Role of Health Care
Professionals
Unprepared for side effects “I didn't even know my body was going to go through that. It hit me like a boom” (Bluethmann et al., 2017; p.5)
“My doctor told me I would probably have night sweats and hot flashes, but that's all I really expected. I didn't
expect the [severe side effects] I had. … It started with pain in my shoulders, and then it moved to my jaw.
Eventually, it moved to every joint in my body.” (Bluethmann et al., 2017; p.5) “I would have liked more
information to prepare for the side effects. I was given lots of information about the side effects of chemotherapy
and how to manage them, but I wasn't expecting the side effects of HT. So perhaps that made it worse” (Brett et al.,
2018; p.293)
Feeling unsupported by HCP “You feel like you don't have all the structures we talked about before [when undergoing chem/radiotherapy], so
now [on hormone therapy]you're winging it, and that's scary” (Braeur et al., 2016; p.993) “This is the one thing that
I do find a lot of women struggling most with, that they feel so … they're just not listened to. They're not being
validated in what they're experiencing.” (Moon et al., 2017; p.22) “I would rather have somebody tell me that they
don't know why I had a reaction to this or that, rather than just make me feel like I'm a child or it's just your
hormones or it's just your mental incapacity” (van Londen et al., 2014; p.6) “I wanted to be followed up. If they're
going to start fiddling with your hormone levels, they should be checking you every three months. There's no
checks and balances. If I had felt I was being followed and people knewwhatwas happening tome, I would have felt
much better. I felt totally alone” (Lambert et al., 2018; p.8)
HCP's influence on adherence “I said ‘I've decided to stop [taking hormone therapy], what do you think?’ And she [oncologist] shrugs and said
‘Fine’. If she had said ‘No, definitely not, I really don't think you should stop’, I probably wouldn't have” (Lambert
et al., 2018; p.7) I had a long conversation with him [GP] about ite he really cared. He swappedme on to this onee
I know he is doing what he can. If you feel someone cares, it kind of encourages you to keep going, if you knowwhat
I mean. [P18 adherer] (Brett et al., 2018; p.293)
Managing HT side
effects
Non-adherence in order to
reduce side effects
“I was walking with crutches and canes for support, but after I stopped taking the tamoxifen, the pain subsided.”
(Bluethmann et al., 2017; p.7) “… the hot flashes. I would wake up during the night and be drenched. I skipped one
month [of ADJUVANT HORMONE THERAPY].” (Humphries et al., 2018; p.8)
Self-help strategies “I read on the internet about looking after myself […] I eat much healthier now, and avoid alcohol and caffeine. A bit
boring, but it helps. The side effects are less now” (Brett et al., 2018; p.293) “Very often I get home (from an
appointment) and I realize that I don't have the full picture, and so then I go to the Internet.” (Pieters et al., 2019;
p.9) “I mentioned it to [my doctor], but I knew it was just one of those things I would have to cope with, so I just
did.” (Bluethmann et al., 2017; p.6)
Social support “I realize, hey, I'm not the only one that's going through this. Other people are going through this too … We're a
community.” (Pieters et al., 2019; p.9) “You can be totally blunt with him. And he just really wants to help do
what's best for you, but he listens to your issues. He doesn't minimize how you're feeling” (Bedi, 2018; p.80)
Weighing up the pros
and cons
Accepting risk of cancer
recurrence
“I've had tamoxifen, and I've had breast cancer. I would rather have breast cancer.” (Bluethmann et al., 2017; p.7)”
“You're counting the days and it becomes like you can't wait for the end [of ADJUVANT HORMONE THERAPY]. I
don't knowwhat's going to happen. It may come back and I'm going to die anyway. So, I'd rather have a good quality
of life while I'm alive and not have side effects” (Lambert et al., 2018; p.8) “I called my doctor and told her I was
going to stop taking Femara, that it was affecting me adversely, and that my quality of life was more important.”
(Bluethmann et al., 2017; p.6)
Fear of cancer recurrence “The advantage they told me, was that it could save me. […] I saw this as prevention against a recurrence.”
(Humphries et al., 2014; p.6) “If it was for anything else other than the cancer I would have stopped it, there's no
questions, but because the cancer is such a big thing, you know the possible return of it, that's the only reason I'm
strugglingwith it” (Moon et al., 2017; p.20) “I will carry on despite how I feel just because it's the only thing I can do
and I'll do anything I can [to stop the cancer returning] because of the kids really e I do want to be around [for
them” (Brett et al., 2018; p.294)
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effects with their HCPs were often not satisfied with the outcome of
the consultation. They expressed a desire for more personalised
advice, describing the guidance they received as “repetitive and too
general” [26]. Some described having their concernsminimised and155perceived HCPs as uncaring about their suffering [30,31]. Women
stated there is a need for more psychological support with side
effects [30,36,37], and more monitoring of side effects to support
them in taking the medication. One individual stated that more
encouragement from her HCP to persist with medication would
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trust in HCP's good intentions and expertise was linked to will-
ingness to follow their advice [26,27,35], therefore, a supportive
relationship with HCPs could potentially improve adherence to
medication. This was highlighted by one participant explaining
they discontinued adjuvant treatment without consulting a doctor
because they felt “nobody was interested” [38].
3.3.3. Managing HT side effects
Many women were proactive in their self-management of side
effects, conducting their own research (largely online) to deepen
their understanding of their medication and identify ways to
reduce side effects. Strategies included: dietary changes, increased
exercise, wearing thinner clothes, taking breaks during household
chores, and minimising activity in swollen limbs [27,28,38]. This
online research led some to reconsider their decision to continue
taking HT [40], as they realised their symptoms were caused by
their medication.
Online breast cancer survivor communities were commonly
utilised as a source of information [26,29,40]. Women valued
experiential support from others who had taken HT and could
provide support on how to manage side effects [26]. These com-
munities were also a significant source of social and emotional
support, as women felt a sense of relief upon realising, “I'm not the
only one that's going through this” [40]. Women also valued the
social support they received from their personal networks, who
helped to support them with side effects and encouraged persis-
tence when their motivation waned [37]. HCPs could play a
particular role in this, as HCPs who listened to women's experi-
ences and did not minimize their side effects [26], were considered
more supportive and encouraging of adherence and persistence.
Some participants made considered decisions not to adhere to
their prescriptions or to discontinue their prescriptions completely
to get relief from the side effects of HT [38]. Participants took
“medication holidays” to alleviate side effects including hot flushes,
night sweats (disrupting sleep), joint pain and depressive symp-
toms, and nausea [29,34,35]. One study [29] stated that women
who were advised to take medication breaks by their HCPs were
more likely to resume their treatment, compared to those women
who took medication breaks on their own initiative. This highlights
the need for HCPs to actively support women experiencing side
effects in order to facilitate HT adherence.
3.3.4. Weighing up the pros and cons
The influence of side effects on quality of life led to many
women reconsidering their decision to persist with treatment. This
decision was influenced by many factors including side effect
severity, fear of cancer recurrence and perceived risk of recurrence.
Side effect severity appears to influence an individual's decision of
whether to persist or discontinue HT. Some women coped rela-
tively well with HT side effects [29], whereas some described the
treatment as “potentially worse than the disease” and “unbearable”
[37]. The intensity of side effects was a key factor in the decision to
discontinue therapy, as many reached a stage where they felt the
advantages of the drugs were outweighed by the burden of side
effects [31,33,34,37]. This was prominent in older women, who
explained they would prioritise quality of life in their remaining
years over minimising the risk of recurrence due to wanting to
“enjoy the life you have left”. Similarly, many expressed a desire to
move on from cancer treatment and resume normality, which they
felt HT was inhibiting [40].
The advantages of HT were well-understood by the majority of
breast cancer survivors. Adjuvant treatment was considered a
“security blanket” [37], giving women hope for remaining cancer-
free in the future [36]. This was a powerful motivator, as women156expressed a constant fear of cancer recurrence, characterising this
worry as, “a sword dangling above your head” [30]. Awareness of
potential recurrence was a factor in anticipated regret. Women
expressedwanting to know that they had “done all the right things”
[36] to prevent recurrence. A recurring sentiment among survivors
was that adjuvant treatment was not optional, and they were
obliged to persist due to family responsibilities [27,36] and a duty to
the people who had supported them through treatment [35].
Managing the side effects from HT was described as a “small price
to pay” [30] for the potential benefits.
Although HT gave some a sense of security against recurrence,
this was often dependent on how much women perceived them-
selves to be at risk. Somewomenwere confident in their decision to
discontinue or persist due to specific characteristics (age, cancer
sensitivity, and cancer hormone receptor status) [35], whereas
some felt oncologists had not been able to give them a clear indi-
cator of their risk of recurrence [27]. Some were sceptical of the
benefits of HT due to the lack of tangible efficacy, and confusion
regarding its influence on risk of recurrence [37]. This demonstrates
an opportunity for HCPs to facilitate adherence, by reminding
women of the purpose of HT treatment, normalising their experi-
ence of side effects [35], and encouraging them to persist [27].
4. Discussion
This qualitative review aimed to identify how side effects of
hormone therapy (HT) can influence breast cancer survivors
adherence to and persistencewith their medication. Identifying the
impact of side effects on adherence to and persistence with HT for
breast cancer survivors is critical for reducing risk of recurrence and
reducing mortality. Four analytical themes were identified as hav-
ing a significant influence on HT adherence and persistence
behaviour. These themes were: “Daily impact of HT side effects”,
“Role of Health Care professionals (HCPs)”, “Managing HT Side effects”,
and “Weighing up the pros and cons”. These findings are consistent
with the results of Clancy et al. (2020) [20] and Lambert et al. (2018)
(19), who both identified that side effects had a considerable
impact on quality of life and consequently adherence and persis-
tence, and that there is a need for more follow-up care and support
from health care professionals. The current review progresses
previous reviews through its detailed examination of the specific
relationship between side effects and adherence and persistence
with HT, whereas earlier reviews of the qualitative literature simply
aimed to identify studies which examined adherence and
persistence.
There is strong evidence that the presence and severity of side
effects can impact on adherence and persistence behaviour [41].
The current review revealed that HT side effects had wide-ranging
impacts on breast cancer survivors' daily life. Musculoskeletal pain
limited mobility and impacted on sleep, which then impacted
cognitive functioning (i.e. concentration and memory), thus
reducing women's ability to work. HT side effects also affected
women's ability to socialise and enjoy fulfilling sexual relation-
ships. Symptom-specific interventions have been trialled, with
some evidence suggesting that use of medications can reduce the
severity of side effects [42]. However, some side effects (i.e. sleep
disturbance, fatigue) cannot be resolved through medical in-
terventions, as pharmacological treatments are not recommended
for long term use [43]. Therefore, psychological interventions such
as mindfulness and/or cognitive behavioural therapy, and lifestyle
interventions such as physical activity, which are effective at
improving sleep and fatigue in a variety of clinical populations
[44,45], also need to be trialled with breast cancer survivors to
assess whether reducing these side effects promotes HT adherence
and persistence.
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tween a reduction in cancer risk and maintaining their quality of
life. This evaluation process appears to be pivotal to the decision to
adhere and persist with adjuvant hormone therapy, as survivors
appear to actively decide if the benefits of treatment outweigh the
detrimental impact side effects have on their quality of life [33,34].
The findings of this review also emphasised how women often felt
unprepared for the side effects of HT. If women are to persist with
HT, then they require adequate information about the benefits of
treatment and the risk of recurrence that is tailored to their needs
[46]. Previous research has suggested that informing women with
breast cancer about HT and potential side effects can be a successful
strategy to enhance adherence [47]. However, providing informa-
tion alone is not sufficient for improving adherence and persistence
[48]. Adequate health care provider support and communication
needs to be provided to support long term adherence and
persistence.
The results of this review also highlighted the significance of the
important role healthcare professionals play in supporting women
to manage HT side effects and encouraging adherence and persis-
tence behaviour. This review has identified that breast cancer pa-
tients who receive HT often receive this treatment whilst in a
transitional period from primary to secondary care, and a result
patients often feel they are no longer a priority or find that they are
not able to receive the specialist care that they require. This lack of
support indicates a missed opportunity for early intervention and
promotion of the benefits of persisting with adjuvant HT, as some
woman reported that more encouragement and support from
healthcare professionals would help them to cope better with their
side effects [19].
A lack of support from healthcare providers leads to survivors
developing their own self-management strategies for dealing with
medication side effects, which in some cases results in non-
adherence [29,34]. Patient-centred communication is a positive
predictor of adherence [49], with evidence suggesting that better
communication improves patient outcomes and reduces the
burden of symptoms [50]. Communication with healthcare pro-
viders and individually tailored approaches are therefore needed
for effective treatment planning [19]. Comprehensive follow-up
care should be provided for women who are prescribed adjuvant
HT so that those experiencing adverse effects can be identified and
supported to continue with their medication as prescribed.
Studies included within this review tended to combine all types
of HT rather than consider any differences between different
treatment approaches. Clinical observations suggest that different
treatments (i.e. Tamoxifen and AI) have different side effect profiles,
albeit with some overlap. This review was not able to disentangle if
therewere any differences between the impact of side effects based
on treatment type, and whether this had any impact on adherence
and persistence. This highlights a limitation of the literature, as
evidence indicates that side effect burden impacts on the decision
to persist with treatment. Therefore, being able to identify if one
treatment option is less impactful may help to promote adherence
and persistence, and would be clinically meaningful for both pa-
tients and practitioners.
A limitation of this review is that it focuses specifically on
women with breast cancer and their experience of HT side effects.
Approximately 350 men are diagnosed with breast cancer annually
in the UK [51], and whilst this is considerably less than the number
of women, it is still an important issue that should be considered in
future research. Menwith breast cancer can also be treated with HT
such as tamoxifen, however they may experience different side
effects. However, there is a lack of research on men with breast
cancers experience of taking HT and they may experience different
side effects or have other barriers to adherence. Another limitation157of this review was that it was not possible to determine the impact
of prior treatment on adherence and persistence, or the impact of
age or ethnicity, which may impact the side effects experienced.
Due to the qualitative nature of the included studies and the lack of
distinctions made in the original studies it is difficult to draw any
conclusions. However, the authors are currently completing a re-
view that focuses on the quantitative literature related to this topic
and are hoping to unpick the impact of prior treatment, age and
ethnicity differences further in that review.
5. Conclusion
This paper aimed to explore how side effects influence adher-
ence and persistence to HT. This review has identified key areas for
developing interventions to improve HT adherence and persistence
in clinical practice. By identifying the precise ways in which side
effects contribute to non-adherence and treatment discontinua-
tion, interventions can be offered which reduce the impact of side
effects and remove some of the barriers to breast cancer survivors
taking their medication as prescribed.
Declaration of competing interest
There are no competing interests to declare.
Acknowledgements
The authors would like to thank the Chief Scientist Office for
supporting this research.
Authors’ contributions
Involved in the development of the search strategy: Nicola
Peddie, Leanne Fleming, Megan Crawford and Diane Dixon.
Involved in conducting the review screening process: Nicola Peddie
and Sommer Agnew. Involved in analysis, contributed to the
writing and review of the manuscript: Nicola Peddie, Sommer
Agnew and Leanne Fleming. Involved in the review of the manu-




The protocol for this review is available on PROSPERO
(CRD42020192481).
Ethics approval and consent to participate
As a systematic review there were no participants.
Funding information
This work was supported by a Chief Scientist Office Catalytic
Research Grant (CGA/19/62).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.breast.2021.05.005.
N. Peddie, S. Agnew, M. Crawford et al. The Breast 58 (2021) 147e159References
[1] CRUK. Breast cancer statistics [Internet]. 2018. Available from: www.
cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type.
[2] Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents
for treatment and prevention of breast cancer [Internet] Int J Clin Pract
2007;61(12):2051. 63. Available from: https://pubmed.ncbi.nlm.nih.gov/
17892469. [Accessed 24 September 2007].
[3] (EBCTCG) EBCTCG. Relevance of breast cancer hormone receptors and other
factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
randomised trials [Internet] Lancet 2011;378(9793):771e84. https://doi.org/
10.1016/S0140-6736(11)60993-8. Available from:.
[4] Moon Z, Moss-Morris R, Hunter MS, Norton S, Hughes LD. Nonadherence to
tamoxifen in breast cancer survivors: a 12 month longitudinal analysis
[Internet] Health Psychol 2019 Oct;38(10):888e99. https://doi.org/10.1037/
hea0000785. Available from:.
[5] Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, et al. Persistence
in patients with breast cancer treated with tamoxifen or aromatase inhibitors:
a retrospective database analysis. Breast Canc Res Treat 2013;138(1):185e91.
[6] Brito C, Portela MC, Vasconcellos MTL de. Factors associated to persistence
with hormonal therapy in women with breast cancer [Internet] Rev Saude
Publica 2014;48(2):284e95. Available from: https://pubmed.ncbi.nlm.nih.
gov/24897050.
[7] Wassermann J, Rosenberg SM. Treatment decisions and adherence to adjuvant
endocrine therapy in breast cancer [Internet] Curr Breast Cancer Rep
2017;9(2):100e10. https://doi.org/10.1007/s12609-017-0248-5. Available
from:.
[8] Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW.
Adherence to adjuvant hormonal therapy among breast cancer survivors in
clinical practice: a systematic review [Internet] Breast Canc Res Treat
2012;134(2):459e78. Available from: https://pubmed.ncbi.nlm.nih.gov/
22689091. [Accessed 12 June 2012].
[9] Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and fa-
cilitators of adjuvant hormone therapy adherence and persistence in women
with breast cancer: a systematic review [Internet] Patient Prefer Adherence
2017;ume 11:305e22. Available from: https://www.dovepress.com/barriers-
and-facilitators-of-adjuvant-hormone-therapy-adherence-and-pe-peer-
reviewed-article-PPA.
[10] Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and
adjuvant endocrine therapy adherence among medicare patients with breast
cancer [Internet] J Clin Oncol 2017;35(1):86e95. Available from: https://
pubmed.ncbi.nlm.nih.gov/28034069. [Accessed 28 October 2016].
[11] Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to
adjuvant hormonal therapy and its relationship to breast cancer recurrence
and survival among low-income women [Internet] Am J Clin Oncol
2013;36(2):181. 7. Available from: https://pubmed.ncbi.nlm.nih.gov/
22314001.
[12] Bosco-Levy P, Jove J, Robinson P, Moore N, Fourrier-Reglat A, Bezin J. Persis-
tence to 5-year hormonal breast cancer therapy: a French national
population-based study [Internet] Br J Canc 2016;115(8):912e9. https://
doi.org/10.1038/bjc.2016.276. Available from:.
[13] Moon Z, Hunter MS, Moss-Morris R, Hughes LD. Factors related to the expe-
rience of menopausal symptoms in women prescribed tamoxifen [Internet].
2016/09/01 J Psychosom Obstet Gynaecol 2017;38(3):226. 35. Available from:
https://pubmed.ncbi.nlm.nih.gov/27583832.
[14] Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, et al.
Early discontinuation and nonadherence to adjuvant hormonal therapy in a
cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28(27):
4120.
[15] Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and
tamoxifen discontinuance in older women with estrogen receptor–positive
breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2004;22(16):3309e15.
[16] Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen
over the five-year course [Internet] Breast Canc Res Treat 2006;99(2):215e20.
https://doi.org/10.1007/s10549-006-9193-0. Available from:.
[17] Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of
menopausal symptoms and their influence on adherence in women with
breast cancer. Climacteric 2014;17(3):252e9.
[18] Bender CM, Gentry AL, Brufsky AM, Casillo FE, Cohen SM, Dailey MM, et al.
Influence of patient and treatment factors on adherence to adjuvant endo-
crine therapy in breast cancer. Oncol Nurs Forum 2014;41(3):274e85.
[19] Lambert LK, Balneaves LG, Howard AF, Gotay CC. Patient-reported factors
associated with adherence to adjuvant endocrine therapy after breast cancer:
an integrative review [Internet] Breast Canc Res Treat 2018;167(3):615e33.
https://doi.org/10.1007/s10549-017-4561-5. Available from:.
[20] Clancy C, Lynch J, OConnor P, Dowling M. Breast cancer patients' experiences
of adherence and persistence to oral endocrine therapy: a qualitative evi-
dence synthesis [Internet] Eur J Oncol Nurs 2020;44:101706. Available from:
https://www.sciencedirect.com/science/article/pii/S1462388919301747?via%
3Dihub. [Accessed 11 March 2020].
[21] Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in
reporting the synthesis of qualitative research: ENTREQ [Internet] BMC Med
Res Methodol 2012;12(1):181. https://doi.org/10.1186/1471-2288-12-181.158Available from:.
[22] Thomas J, Harden A. Methods for the thematic synthesis of qualitative
research in systematic reviews [Internet] BMC Med Res Methodol 2008;8(1):
45. https://doi.org/10.1186/1471-2288-8-45. Available from:.
[23] Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodolog-
ical guidance for systematic reviewers utilizing meta-aggregation. Int J Evid
Base Healthc 2015 Sep;13(3):179e87.
[24] Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a
critical review. BMC Med Res Methodol 2009;9(1).
[25] Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, et al. Online discussion
of drug side effects and discontinuation among breast cancer survivors.
Pharmacoepidemiol Drug Saf 2013;22(3):256e62.
[26] Bedi JS, Charron E, Franco RA, Olinger M, Dickes L, Mayo R. Elucidating the
endocrine therapy experience of South Carolina breast cancer survivors. J Clin
Oncol 2018;36(7_suppl):186.
[27] Brett J, Boulton M, Fenlon D, Hulbert-Williams NJ, Walter FM, Donnelly P, et al.
Adjuvant endocrine therapy after breast cancer: a qualitative study of factors
associated with adherence. Patient Prefer Adherence 2018;12:291e300.
[28] Cheng H, Sit JWH, Cheng KKF. A qualitative insight into self-management
experience among Chinese breast cancer survivors [Internet] Psycho Oncol
2017;26(7):1044e9. https://doi.org/10.1002/pon.4279. Available from:.
[29] Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, et al.
A hard pill to swallow: a qualitative study of women's experiences of adjuvant
endocrine therapy for breast cancer. BMJ Open 2014;4(6):1e10.
[30] Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Understanding tamoxifen
adherence in women with breast cancer: a qualitative study [Internet] Br J
Health Psychol 2017;22(4):978e97. https://doi.org/10.1111/bjhp.12266.
Available from:.
[31] van Londen GJ, Donovan HS, Beckjord EB, Cardy AL, Bovbjerg DH,
Davidson NE, et al. Perspectives of postmenopausal breast cancer survivors on
adjuvant endocrine therapy-related symptoms [Internet] Oncol Nurs Forum
2014;41(6):660e8. Available from: https://pubmed.ncbi.nlm.nih.gov/
25355021.
[32] Wells KJ, Pan TM, Vazquez-Otero C, Ung D, Ustjanauskas AE, Mu~noz D, et al.
Barriers and facilitators to endocrine therapy adherence among underserved
hormone-receptor-positive breast cancer survivors: a qualitative study
[Internet] Support Care Canc 2016;24(10):4123. 30. Available from: https://
pubmed.ncbi.nlm.nih.gov/27146492.
[33] Ahlstedt Karlsson S, Wallengren C, Olofsson Bagge R, Henoch I. “It is not just
any pill”dwomen’s experiences of endocrine therapy after breast cancer
surgery. Eur J Canc Care 2019;28(3):1e8.
[34] Bluethmann SM, Murphy CC, Tiro JA, Mollica MA, Vernon SW,
Bartholomew LK. Deconstructing decisions to initiate, maintain, or discon-
tinue adjuvant endocrine therapy in breast cancer survivors: a mixed-
methods study. Oncol Nurs Forum 2017;44(3):E101e10.
[35] Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L, et al.
Women's beliefs on early adherence to adjuvant endocrine therapy for breast
cancer: a theory-based qualitative study to guide the development of com-
munity pharmacist interventions [Internet] Pharmacy 2018;6(2):53. Available
from: http://www.mdpi.com/2226-4787/6/2/53.
[36] Iacorossi L, Gambalunga F, Fabi A, Giannarelli D, Marchetti A, Piredda M, et al.
Adherence to oral administration of endocrine treatment in patients with
breast cancer: a qualitative study. Canc Nurs 2018;41(1):E57e63.
[37] Lambert LK, Balneaves LG, Howard AF, Chia SK, Gotay CC. Understanding
adjuvant endocrine therapy persistence in breast Cancer survivors [Internet]
BMC Canc 2018;18(1):732. https://doi.org/10.1186/s12885-018-4644-7.
Available from:.
[38] Brauer ER, Ganz PA, Pieters HC. “Winging it”: how older breast cancer sur-
vivors persist with aromatase inhibitor treatment. J Oncol Pract 2016;12(12).
e991e1000.
[39] Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women's
experiences of hormonal therapy for breast cancer: exploring influences on
medication-taking behaviour [Internet] Support Care Canc 2015;23(11):
3115e30. Available from: http://link.springer.com/10.1007/s00520-015-
2685-x.
[40] Pieters HC, Green E, Khakshooy S, Sleven M, Stanton AL. A qualitative com-
parison of how older breast cancer survivors process treatment information
regarding endocrine therapy [Internet] PloS One 2019;14(1):e0210972.
https://doi.org/10.1371/journal.pone.0210972. Available from:.
[41] Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K. Identifying the de-
terminants of adjuvant hormonal therapy medication taking behaviour in
women with stages IeIII breast cancer: a systematic review and meta-analysis
[Internet] Patient Educ Counsel 2015;98(12):1524e39. Available from: http://
www.sciencedirect.com/science/article/pii/S0738399115002347.
[42] Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy
for breast cancer [Internet] Expert Rev Anticancer Ther 2018;18(11):1101e12.
https://doi.org/10.1080/14737140.2018.1520096. Available from:.
[43] National Institute for Health and Care Excellence. National Institute for health
and care excellence (NICE) clinical knowledge summaries (CKS).Insomnia
[Internet]. Available from: https://cks.nice.org.uk/topics/insomnia/.
[44] Johnson JA, Rash JA, Campbell TS, Savard J, Gehrman PR, Perlis M, et al.
A systematic review and meta-analysis of randomized controlled trials of
cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep
Med Rev 2016;27:20e8.
[45] Tomlinson D, Diorio C, Beyene J, Sung L. Effect of exercise on cancer-related
N. Peddie, S. Agnew, M. Crawford et al. The Breast 58 (2021) 147e159fatigue: a meta-analysis [Internet] Am J Phys Med Rehabil 2014;93(8).
Available from: https://journals.lww.com/ajpmr/Fulltext/2014/08000/Effect_
of_Exercise_on_Cancer_Related_Fatigue__A.5.aspx.
[46] Bourmaud A, Rousset V, Regnier-Denois V, Collard O, Jacquin JP, Merrouche Y,
et al. Improving adherence to adjuvant endocrine therapy in breast cancer
through a therapeutic educational approach: a feasibility study. Oncol Nurs
Forum 2016;43(3):E94e103.
[47] Heisig SR, Shedden-Mora MC, von Blanckenburg P, Schuricht F, Rief W,
Albert U-S, et al. Informing women with breast cancer about endocrine
therapy: effects on knowledge and adherence [Internet] Psycho Oncol
2015;24(2):130e7. https://doi.org/10.1002/pon.3611. Available from:.
[48] Finitsis DJ, Vose BA, Mahalak JG, Salner AL. Interventions to promote159adherence to endocrine therapy among breast cancer survivors: a meta-
analysis. Psycho Oncol 2019;28(2):255e63. https://doi.org/10.1002/pon.4959.
Available from:.
[49] Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hor-
mone therapy in low-income women with breast cancer: the role of provider-
patient communication. Breast Canc Res Treat 2013;137(3):829e36.
[50] Street RL, Makoul G, Arora NK, Epstein RM. How does communication heal?
Pathways linking clinicianepatient communication to health outcomes
[Internet] Patient Educ Counsel 2009;74(3):295e301. Available from: http://
www.sciencedirect.com/science/article/pii/S0738399108006319.
[51] UK CR. Breast cancer in men. 2020.
